Arrowhead focuses on developing medicines that treat intractable diseases by using ribonucleic acid interference mechanism.
Business Model:
Revenue: $278.3M
Employees: 201-500
Address: 177 East Colorado Boulevard
City: Pasadena
State: CA
Zip: 91105
Country: US
Arrowhead focuses on developing medicines that treat intractable diseases by using ribonucleic acid interference mechanism.
Contact Phone:
+16263043400
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
2/8/1995
Ticker Symbol:
ARWR
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2006 | Calando Pharmaceuticals | Venture Round | 10M |
1/2011 | Calando Pharmaceuticals | Venture Round | 1M |
1/2011 | Calando Pharmaceuticals | Venture Round | 0 |
4/2006 | Calando Pharmaceuticals | Venture Round | 0 |
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2013 | Post-IPO Equity | $36M | 5/2007 | Post-IPO Equity | 1 | $16.5M |
York Capital Management York Capital Management |
1/2010 | Post-IPO Equity | $3.2M | 8/2016 | Post-IPO Equity | 1 | $45M |
OrbiMed OrbiMed OrbiMed OrbiMed |
1/2017 | Post-IPO Equity | $0 |
Silence Therapeutics Silence Therapeutics Silence Therapeutics Silence Therapeutics |
8/2009 | Post-IPO Equity | $2.8M | 10/2006 | Post-IPO Equity | $10M | 10/2013 | Post-IPO Equity | 1 | $60M |
RA Capital Management RA Capital Management |
12/2019 | Post-IPO Equity | $266.8M | 1/2017 | Post-IPO Equity | 1 | $9.6M |
Silence Therapeutics Silence Therapeutics Silence Therapeutics Silence Therapeutics |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|